Metropolitan Life Insurance CO Eagle Pharmaceuticals, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

35 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$25.06 - $34.09 $5,162 - $7,022	-206 Reduced 27.03%	556 $15,000
Q4 2022 Jun 14, 2023	BUY	$24.98 - $39.77 $5,145 - $8,192	206 Added 37.05%	762 $22.3 Million
Q3 2022 Jun 14, 2023	BUY	$26.42 - $47.12 $5,442 - $9,706	206 Added 37.05%	762 $20.1 Million
Q2 2022 Jun 20, 2023	BUY	$41.26 - $51.35 $8,499 - $10,578	206 Added 37.05%	762 $33,000
Q1 2022 Jun 20, 2023	BUY	$44.58 - $52.6 $9,183 - $10,835	206 Added 37.05%	762 $37,000
Q1 2022 Mar 30, 2023	SELL	$44.58 - $52.6 $123,798 - $146,070	-2,777 Reduced 78.47%	762 $37,000
Q1 2022 May 12, 2022	SELL	$44.58 - $52.6 $123,798 - $146,070	-2,777 Reduced 78.47%	762 $38,000
Q4 2021 Jun 21, 2023	BUY	$45.82 - $56.9 $136,681 - $169,732	2,983 Added 536.51%	3,539 $180,000
Q3 2021 Jun 21, 2023	BUY	$43.79 - $55.78 $130,625 - $166,391	2,983 Added 536.51%	3,539 $197,000
Q2 2021 Jun 21, 2023	BUY	$36.86 - $44.5 $109,953 - $132,743	2,983 Added 536.51%	3,539 $151,000
Q2 2021 Aug 16, 2021	BUY	$36.86 - $44.5 $130,300 - $157,307	3,535 Added 88375.0%	3,539 $151,000
Q1 2021 Jun 26, 2023	BUY	$40.32 - $50.97 $120,274 - $152,043	2,983 Added 536.51%	3,539 $148 Million
Q1 2021 May 14, 2021	SELL	$40.32 - $50.97 $142,531 - $180,178	-3,535 Reduced 99.89%	4 $148,000
Q4 2020 Jun 22, 2023	BUY	$41.72 - $51.34 $124,450 - $153,147	2,983 Added 536.51%	3,539 $164,000
Q3 2020 Jun 26, 2023	BUY	$37.02 - $51.28 $110,430 - $152,968	2,983 Added 536.51%	3,539 $150,000
Q2 2020 Jun 26, 2023	BUY	$43.24 - $55.02 $128,984 - $164,124	2,983 Added 536.51%	3,539 $169,000
Q2 2020 Mar 30, 2023	BUY	$43.24 - $55.02 $1,124 - $1,430	26 Added 0.74%	3,539 $169,000
Q2 2020 Aug 14, 2020	BUY	$43.24 - $55.02 $1,124 - $1,430	26 Added 0.74%	3,539 $170,000
Q1 2020 Jul 12, 2023	BUY	$34.37 - $60.07 $101,632 - $177,626	2,957 Added 531.83%	3,513 $161,000
Q4 2019 Jul 12, 2023	BUY	$54.32 - $64.31 $160,624 - $190,164	2,957 Added 531.83%	3,513 $211,000
Q3 2019 Jul 12, 2023	BUY	$53.25 - $59.98 $157,460 - $177,360	2,957 Added 531.83%	3,513 $198,000
Q2 2019 Jul 12, 2023	BUY	$46.61 - $58.45 $137,825 - $172,836	2,957 Added 531.83%	3,513 $195,000
Q1 2019 Jul 13, 2023	BUY	$38.66 - $51.82 $114,317 - $153,231	2,957 Added 531.83%	3,513 $177,000
Q1 2019 Mar 30, 2023	BUY	$38.66 - $51.82 $106,353 - $142,556	2,751 Added 361.02%	3,513 $177,000
Q1 2019 May 16, 2019	SELL	$38.66 - $51.82 $676,395 - $906,642	-17,496 Reduced 83.28%	3,513 $177,000
Q1 2019 May 15, 2019	BUY	$38.66 - $51.82 $676,395 - $906,642	17,496 Added 498.04%	21,009 $479,000
Q4 2018 Jul 13, 2023	BUY	$36.72 - $67.73 $108,581 - $200,277	2,957 Added 531.83%	3,513 $141,000
Q4 2018 Feb 14, 2019	BUY	$36.72 - $67.73 $101,016 - $186,325	2,751 Added 361.02%	3,513 $142,000
Q3 2018 Jul 13, 2023	BUY	$66.65 - $83.86 $197,084 - $247,974	2,957 Added 531.83%	3,513 $244 Million
Q3 2018 Nov 14, 2018	SELL	$66.65 - $83.86 $183,354 - $230,698	-2,751 Reduced 78.31%	762 $53,000
Q2 2018 Aug 15, 2018	BUY	$51.25 - $76.62 $32,902 - $49,190	642 Added 22.36%	3,513 $0
Q1 2018 May 15, 2018	BUY	$52.16 - $66.86 $13,822 - $17,717	265 Added 10.17%	2,871 $0
Q4 2017 Feb 15, 2018	SELL	$49.6 - $60.87 $149,990 - $184,070	-3,024 Reduced 53.71%	2,606 $139,000
Q3 2017 Nov 14, 2017	SELL	$46.62 - $60.36 $11,748 - $15,210	-252 Reduced 4.28%	5,630 $336,000
Q2 2017 Aug 14, 2017	BUY	N/A	5,882	5,882 $464,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account